PRESS RELEASES More events are coming soon. Keyword Search Year: 202120202019201820172016201520142013 02/25/08 Summary ToggleFirst Patient Treated with Novel “First-in-Class” Anti-Cancer Drug Printer Friendly Releasefe4a5acb-1679-4c19-bff3-34c5caf41b49_2010115.pdf 14.4 KB 01/09/08 Summary ToggleTRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody Printer Friendly Release0c5df184-d831-40a8-b36e-b15cf94d5f70_2010116.pdf 11.3 KB 11/02/07 Summary ToggleTRACON Pharmaceuticals to Present at the Rodman & Renshaw 9th Annual Healthcare Conference Printer Friendly Releasefc5ead9a-58f4-471d-85b9-3e0df1e81301_2010117.pdf 9.7 KB 03/16/07 Summary ToggleMicromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment Printer Friendly Releasec95b88d3-c790-45fd-8db0-2ea8ac850fb7_2010119.pdf 16.7 KB 11/03/06 Summary ToggleTracon Pharmaceuticals, Inc. announces presentation at Rodman & Renshaw 8th Annual Healthcare Conference Printer Friendly Release3b0f76c4-664b-4594-a2ae-2fd75652c0f6_2010120.pdf 6.6 KB 10/12/06 Summary ToggleCase Licenses Methoxyamine to Tracon Printer Friendly Release59f0f14a-c2a8-4415-b769-1b629c275c5a_2010121.pdf 14.7 KB 08/02/06 Summary ToggleTracon Pharmaceuticals appoints Charles P.Theuer, M.D., Ph.D as President and Chief Executive Officer Printer Friendly Release4158c9c2-d21b-4a4a-a11a-73b709a9bca5_2010122.pdf 8.4 KB 03/14/06 Summary ToggleTRACON Pharmaceuticals assembles industry-leading management team to support development of targeted cancer therapy pipeline Printer Friendly Release838f81f6-771f-40b6-99e9-8be67b7a48db_2010123.pdf 17.6 KB 04/16/05 Summary ToggleLexington Pharmaceuticals changes name to TRACON Pharmaceuticals, Inc. Lexington Pharmaceuticals announced that it has changed its name to TRACON Pharmaceuticals, Inc., and has moved the company from New York, New York to San Diego, California. Printer Friendly Releasefa84284c-e508-4765-90ce-d3ad5de2a7cf_2010130.pdf 6.1 KB 04/01/05 Summary ToggleLexington Pharmaceuticals names Bert Liang, MD MBA as President and CEO. Dr. Liang was formerly Vice President of New Ventures, at Biogen Idec. Printer Friendly Release64aedcd4-e4e8-47eb-b2c1-fb488d84bb47_2010131.pdf 5.4 KB Pagination First page First Previous page Previous … Page 21 Page 22 Page 23 Current page 24
